Actelion PAH Franchise

Actelion has strived to prioritize new medications for Pulmonary Arterial Hypertension (PAH). The launch of Opsumit and Uptravi have made great strides for treatment of this disease. Our team dedicated to make sure that we delivered timely supporting products to meet the demand of materials and digital projects that would educate and promote to HCPs and Patient population.

ACTELION PATHWAYS VISION FOR PATIENT ACCESS AND ATTENTIVENESS TO PATIENT NEEDS THEY NEEDED MULTIPLE PROGRAMS THAT WERE HCP FACING AND INFORMED THE AUDIENCE.

IGNITE WAS TO CREATE A POSITIVE AND ILLUMINATING SENSE OF ACCOMPLISHMENT WITH THE LAUNCH OF UPTRAVI AND OPSUMIT. 

THE ACTELION PATHWAYS BRAND 2018 WITH ROLLOUT VIDEOS FOR BRAND LAUNCH AND TIMELINE VIDEOS AND INTERACTIVE
FOR PAH FRANCHISE

ACTELION PORTAL FOR HCPS. COMPLETED FOR 4TH QT 2016 AND TO RUN THROUGH 2017.
COMPLETE REDESIGN AND NEW TECHNOLOGY TO REPLACE OUTDATED SYSTEM

PAH FRANCHISE QUARTERLY NEWSLETTER AND DIGITAL CAMPAIGN 2016-17
RECAP OF ALL PROGRAMS WITHIN THE ACTELION PAH GROUP
AUDIENCE HCPS AND INTERNAL PROMOTIONAL
 

You may also like

Pfizer Hemophilia "STEPS FOR LIVING" Patient Web Site
2021
Otsuka Rexulti Specialty Pharmacy Site
2018
Ads
2020
Videos
2021
Print and Digital
2018
Love Life CANCER NETWORK
2021
Logos and Trademarks
2018
Pfizer Biosimilars
2020
↑Back to Top